News

Presentation | South-West Connect Event

Oct 27, 2021

Presentation | South-West Connect Event

Video | Proactive Biosciences Webinar

Sep 28, 2021

Video | Proactive Biosciences Webinar

Investor Webinar | Drug Development Programs and Overview

Aug 24, 2021

Investor Webinar | Drug Development Programs and Overview

Investor Webinar | Emyria validated care model

Jun 09, 2021

Investor Webinar | Emyria validated care model

Health Europa E-Book

Apr 30, 2021

Health Europa E-Book

Investor Webinar | Emyria and Cann Group Partnership

Apr 09, 2021

Investor Webinar | Emyria and Cann Group Partnership

Emyria and Cann Group to partner on Schedule 3 medicine CBD product registration

Mar 28, 2021

Emyria and Cann Group to partner on Schedule 3 medicine CBD product registration

Opinion | Psychedelic substances represent a chance to alleviate Australia’s mental health crisis

Mar 20, 2021

Opinion | Psychedelic substances represent a chance to alleviate Australia’s mental health crisis

Presentation: Dr Michael Winlo on Broker Briefing

Mar 16, 2021

Presentation: Dr Michael Winlo on Broker Briefing

1
2
3
Next

Contact Us

Phone 1300 436 363

Email info@emyria.com

Recent Tweets

$EMD mentioned by kalkineau as an #ASX healthcare growth stock expected to perform well in the future with a good… https://t.co/D1PxNXeEn5

$EMD to commence Phase 1 trials to assess the safety and bioavailability of its ultra-pure #CBD capsules (EMD-RX5)… https://t.co/5cTC5NUZbC

$EMD features in kalkineau as one of the five ASX-listed #multibagger stocks to watch this year with high growth p… https://t.co/qDvIQ1fVhe